Summary
Tranquillizing drugs are of great interest to anaesthesiologists. The investigation of new compounds continues in the hope of finding even more satisfactory agents.
The pharmacology of triflupromazine is briefly reviewed and also the clinical findings of other investigators.
This report deals with the clinical findings after giving tiriflupromazine to 1,577 patients (postoperatively, 30; pre-anaesthetic-loca 655, general 725, spinal 167).
Favourable effects including good psychic sedation without mental elouding; significant decrease in postoperative nausea and vomiting; moderate potentiation of narcotics; slight potentiation of barbiturates, minimal potentiation of anaesthetic agents; no respiratory depression or evidence of toxicity to the renal, hepatic or haemopoielic systems.
Better sedation is attained by combination with small amounts of meperidine and/or pentobarbital Side-effects are minimal if dosage of all agents is chosen with care. Such combinations are considered very satisfactory prior to local analgesia.
Though some hypotension was seen, its incidence and severity can be minimized by careful selection of dosage.
Further investigation of this agent is considered desirable
Résumé
Les substances tranquillisantes sont ďun grand intérêt pour les anesthésio-logues. La recherche de nouveaux produits se poursuit dans ľespoir de trouver des médicaments plus satisfaisants.
Nous avons étudié brièvement la pharmacologic de triflupromazine (Vesprin®) les résultats cliniques ďautres chercheurs.
Ce travail présente les résultats cliniques de ľusage de triflupromazine chez 1,577 malades (dont 30 cas apiès ľopération et, avant ľopération, 655 cas de locale, 725 de générate et 167 de rachidienne).
Nous avons observé, parmi les effets désirables, un calme psychique sans obnubilation mentale; une diminution appréciable des nausées et vomissements post-opératoires, une potentialisation légère des narcotiques, de même qu’une potentiahsation légère des barbituriques et une potentialisation moindre des agents anesthésiques; aucune dépression respiratoire, aucune manifestation de toxicité sur Ie rem, le foie ou le système hémopoitique.
On obtient une meilleure sédation si on ľassocie au mepéridine ou au pentobarbital. Les effets indésirables sont réduits si ľon choisit le dosage avec soin. Avant ľanesthésie locale, ces mélanges donnent de bons résultats.
En déprit du fait que nous aivons observé des cas ďhypotension, cette hypotension peut être raréfiée et moins sévère si ľon choisit bien le dosage.
Il s’impose de faire de plus amples recherches sur cette substance.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fabing, H. D. A New Blocking Agent against the Development of Experimental LSD-25 Psychosis. Paper read before the American Psychiatric Association, Galveston, Texas.
Martin, M. G. How to Assess the Tranquilizers. Modern Med.,27 (5): 256 (1959).
Dobktn, A. B. Efficacy of Ataractic Drugs in Clinical Anaesthesia: A Review. Canad. Anaesth Soc. J. 5 (2). 177 (1958).
Hunt, W. H. H. Report of Pharmacologic Tests. Squibb Institute for Medical Research (Feb. 16, 1956).
Poutsiaka, J. W. Report of Pharmacologic Tests Squibb Institute for Medical Research (Feb. 15, 1956).
Burke, J. C. A Summary of Pharmacologic Studies (MC 4703) Squibb Institute for Medical Research (March 8, 1956).
Toxicologic Studies on SQ 4703 Pharmacology Division of the Squibb Institute for Medical Research (June 10, 1957)
Piala, J. J.,Hassert, G. L., Jr.,High, J. P., &Burke, J. C. Pharmacology of Vesprin Monographs on Therap 2; 214 (1957).
Mover, J. H., &Pevey, J. K. Report to the Squibb Institute for Medical Research (June 20 and July 29, 1957).
Goldman, D. Observations on the Clinical Use of Vesprin. Monographs on Therapy2:177 (1957).
Goldman, D. The Results of Treatment of Psychotic States with Newer Phenothiazme Compounds Effective in Small Doses. Am J Med Sc.235 67 (1958)
Gallagher, W. J., &Pfeiffer, C. C. One Year of Vesprin Therapy in Chrome Schizophrenia. Monographs on Therapy 2: 188 (1957)
Niswander, G. D., Lind, S., &Schlesinger, J. Vesprin in the Treatment of Mental Illness. Monographs on Therapy 2: 184 (1957).
Freed, H. Some Preliminary Observations on the Use of Vesprin in Children and Adults. Monographs on Therapy 2: 197 (1957).
Azima, H. The Effects of Vesprin in Mental Syndromes (A Preliminary Report) Monographs on Therapy2: 203 (1957). Vesprin and Mopazme Two New Phenotropic Substances. Am J. Psychiatry114: 747 (1958)
Stone, H. H. Report to the Squibb Institute for Medical Research (July 9, 1957, Sept, 1957).
Westphal, R. D. Report to the Squibb Institute for Medical Research (Sept 24, 1957)
Adriani, J. Report to the Squibb Institute for Medical Research (Oct 2, 1957)
Stone, H. H. Preanesthetic Sedation With Vesprin Squibb. Clinical Research Notes 2 (2): 3 (1959)
Wentzler, J. D. Intravenous Use of Vesprin as Adjundtive Medication to Block Anesthesia Squibb. Clinical Research Notes2 (2). 8 (1959).
Weber, C. E. Vesprm as an Adjunct to Obstetrical Analgesia during Labor Squibb. Clinical Research Notes 2(2) 8 (1959).
Bowman, H. W. Postoperative Nausea and Vomiting Controlled with Vesprm. Squibb. Clinical Research Notes. 2 (2): 7 (1959).
Hopktn, D. A. B., &Brown, D. The Reticular System and Chlorpromazme. Anaesthesia 23 (3): 306 (1958)
Lear, E., Chiron, A. E., &Pallin, I. M. A Clinical Study of Mechamsms of Action of Chlorpromazme. J.A. M. A.163 30 (1957)
Author information
Authors and Affiliations
Additional information
Vesprin® is the trade name of triflupiromazine Squibb
Rights and permissions
About this article
Cite this article
Davies, J.I., Hansen, J.M. & Angell, S.N. Triflupromazine (vesprin®) in anaesthesia: a clinical evaluation. Can. Anaes. Soc. J. 6, 375–384 (1959). https://doi.org/10.1007/BF03021286
Issue Date:
DOI: https://doi.org/10.1007/BF03021286